RESUMEN
Non-traumatic osteonecrosis of the femoral head (ONFH) usually affects adults younger than 50 years and frequently leads to femoral head collapse and subsequent arthritis of the hip.It is becoming more prevalent along with increasing use of corticosteroids for the adjuvant therapy of leukemia and other myelogenous diseases as well as management of organ transplantation. This review updated knowledge on the pathogenesis, classification criteria, staging system, and treatment of ONFH.
RESUMEN
Osteonecrosis of the femoral head (ONFH) is a devastating disease frequently leading to femoral head collapse and hip arthritis. Specifically, non-traumatic ONFH primarily affects young and middle-aged adults. Although compromised local circulation of the femoral head seems to be pathognomonic for the disease, the pathogenesis is perplexing and continues to be an area of scrutiny and research. Comprehension of the pathogenesis is of crucial importance for developing and guiding treatments for the disease. Therefore, we provide an up-to-date consensus on the pathogenesis of non-traumatic ONFH.
RESUMEN
Non-traumatic osteonecrosis of the femoral head (ONFH) usually affects adults younger than 50 years and frequently leads to femoral head collapse and subsequent arthritis of the hip.It is becoming more prevalent along with increasing use of corticosteroids for the adjuvant therapy of leukemia and other myelogenous diseases as well as management of organ transplantation. This review updated knowledge on the pathogenesis, classification criteria, staging system, and treatment of ONFH.
RESUMEN
Osteonecrosis of the femoral head (ONFH) is a devastating disease frequently leading to femoral head collapse and hip arthritis. Specifically, non-traumatic ONFH primarily affects young and middle-aged adults. Although compromised local circulation of the femoral head seems to be pathognomonic for the disease, the pathogenesis is perplexing and continues to be an area of scrutiny and research. Comprehension of the pathogenesis is of crucial importance for developing and guiding treatments for the disease. Therefore, we provide an up-to-date consensus on the pathogenesis of non-traumatic ONFH.
RESUMEN
The present study evaluates the pre-treatment child and family characteristics as well as the parental motives and experienced barriers when ending prematurely a weight loss programme for their obese child, in accordance with the 'barriers-to-treatment model' and subsequent research on dimensions underlying treatment termination decision. Treatment seeking youngsters (n = 72) with a mean of 10.46 years (SD = 2.56) were followed over a 1-year period. Dropout, child and family characteristics were measured both during assessment and treatment. The 'barriers-to-treatment' data were collected at the 1-year follow-up via mail (response rate = 65%; n = 47). Results showed that dropout could be successfully predicted at intake by age, psychopathology in the child and motivation of the parents. Results indicated further that there are few differences in total barriers score between completers and non-completers. Item content analysis revealed two themes that were more often reported by non-completers (appointment arrangements and perceived relevance of treatment). The hypothesis that non-completers (compared to completers) experienced more barriers that burden their willingness to continue a weight loss programme could not be confirmed. Besides demographic characteristics, specifically motivation of the parents at intake seems an important area for future research.